No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection
Journal
Clinical Infectious Diseases
Journal Volume
63
Journal Issue
9
Pages
1202-1204
Date Issued
2016
Author(s)
Abstract
Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation. ? The Author 2016.
Subjects
ALT flare; HBV reactivation; HCV/HBV coinfection
SDGs
Other Subjects
alanine aminotransferase; hepatitis B core antibody; ledipasvir plus sofosbuvir; virus DNA; antivirus agent; benzimidazole derivative; fluorene derivative; ledipasvir; sofosbuvir; abnormal laboratory result; adult; aged; alanine aminotransferase blood level; antiviral therapy; Article; blood sampling; cohort analysis; combination drug therapy; compensated liver cirrhosis; controlled study; female; Hepatitis B virus; hepatitis C; human; Korea; major clinical study; male; multicenter study (topic); phase 3 clinical trial (topic); prevalence; priority journal; side effect; Taiwan; virus load; virus reactivation; clinical trial; combination drug therapy; complication; drug effects; hepatitis B; hepatitis C; middle aged; mixed infection; phase 3 clinical trial; virology; virus activation; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Virus Activation
Publisher
Oxford University Press
Type
journal article